Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC930 in Steroid-Refractory Acute Graft Versus Host Disease
NCT04883918Phase 2Not yet recruiting
- Sponsor
- ASC Therapeutics
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of ASC930 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by ASC Therapeutics. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
ASC930
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04883918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883918.